RFK Jr. Tells Joe Rogan He’s About to Unleash 14 Banned Peptides
Summary
RFK Jr. aims to overturn the FDA's late 2023 ban on specific peptide compounding, signaling a potential shift in regulatory policies that could impact the pharmaceutical landscape and access to these treatments.
Key Insights
What are peptides in the context of the FDA ban?
Peptides are short chains of amino acids used in compounding drugs, but the FDA has restricted certain ones like MOTs-C, thymosin beta-4 fragment, ipamorelin acetate, and selank acetate due to risks such as immunogenicity, aggregation, peptide impurities, and lack of human safety data for specific administration routes.[4]
Sources:
[1]
Why did the FDA ban compounding of these peptides?
The FDA banned or restricted compounding of specific peptides in late 2023 under sections 503A and 503B due to significant safety risks, including potential immunogenicity from aggregation and impurities, complexities in characterization, and insufficient safety data for human use, prohibiting pharmacies from using their bulk powders.[4][5]